Saturday, September 12, 2026

---

Overview

Moderator – Dr. Erin Kelly

---

Details

Learning Objectives: • Describe updated PSC/PSC-IBD epidemiology in Ontario • Discuss risk stratification and prognosis, emerging diagnostics and novel therapeutics in PSC • Discuss novel therapeutic treatment options in MASLD • Discuss updated treatment guidelines for Hepatitis B and novel therapies for Hepatitis D • Discuss pathophysiology and impact of frailty and sarcopenia in patients with advanced liver disease